Sex Disparities in <i>MGMT</i> Promoter Methylation and Survival in Glioblastoma: Further Evidence from Clinical Cohorts.

As illustrated, MOS was longest for women (9.7 months, CI 7.5–11.9) and men (9.0 months, CI 7.4–10.6) with m MGMT , compared to women (7.5 months, CI 2.9–12.0) and men (6.8 months (CI 5.8–7.9) with u MGMT , although numbers were small and differences did not reach statistical significance ( p = 0.056, Log-rank) ( Figure 1 d).

also in 111,027 other papers